ANDERSON VICENTE DE PAULA

Índice h a partir de 2011
7
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina
LIM/52 - Laboratório de Virologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Revista / Livro: Plos One ×

Resultados de Busca

Agora exibindo 1 - 4 de 4
  • article 0 Citação(ões) na Scopus
    Detailed characterization of Redondovirus in saliva of SARS-CoV-2-infected individuals in Sao Paulo, Brazil
    (2023) COSTA, Antonio Charlys da; MENDES-CORREA, Maria C.; TOZETTO-MENDOZA, Tania Regina; VILLAS-BOAS, Lucy S.; PAULA, Anderson Vicente de; PAIAO, Heuder Gustavo Oliveira; LEAL, Fabio E.; FERREIRA, Noely E.; HONORATO, Layla; LEAL, Elcio; GRANDI, Giuliano; MORAIS, Vanessa dos Santos; MANULI, Erika R.; SABINO, Ester C.; WITKIN, Steven S.
    BackgroundRedondovirus (ReDoV) is a DNA virus present in the respiratory tract of many healthy individuals. Since SARS-CoV-2, the virus responsible for COVID-19, also primarily infects the same site, we evaluated whether ReDoV was present at increased frequency in patients with COVID-19 and influenced infection parameters.MethodsSaliva samples were collected weekly from 59 individuals with COVID-19 and from 132 controls. ReDoV was detected by polymerase chain reaction and the genotypes were identified by metagenomics. Torque Teno Virus (TTV) in these samples were previously reported.ResultsReDoV was detected in saliva more frequently from COVID-19 patients (72.9%) than from controls (50.0%) (p = 0.0015). There were no associations between ReDoV detection and either continuous or intermittent SARS-CoV-2 shedding, the duration of SARS-CoV-2 detection in saliva, patients' sex or if infection was by the B1 or Gamma strain. The two ReDoV strains, Brisavirus and Vientovirus, were present in equivalent frequencies in ReDoV-positive COVID-19 patients and controls. Phylogenetic analysis suggested that the two ReDoV strains in Brazil were similar to strains previously detected on other continents.ConclusionReDoV expression in saliva is increased in males and females in Brazil with mild COVID-19 but its presence does not appear to influence properties of the SARS-CoV-2 infection.
  • article 0 Citação(ões) na Scopus
    An international, interlaboratory ring trial confirms the feasibility of an extraction-less ""direct"" RT-qPCR method for reliable detection of SARS-CoV-2 RNA in clinical samples
    (2022) MILLS, Margaret G.; BRUCE, Emily; HUANG, Meei-Li; CROTHERS, Jessica W.; HYRIEN, Ollivier; OURA, Christopher A. L.; BLAKE, Lemar; JORDAN, Arianne Brown; HESTER, Susan; WEHMAS, Leah; MARI, Bernard; BARBY, Pascal; LACOUX, Caroline; FASSY, Julien; VIAL, Pablo; VIAL, Cecilia; MARTINEZ, Jose R. W.; OLADIPO, Olusola Olalekan; INUWA, Bitrus; SHITTU, Ismaila; MESEKO, Clement A.; CHAMMAS, Roger; SANTOS, Carlos Ferreira; DIONISIO, Thiago Jose; GARBIERI, Thais Francini; PARISI, Viviane Aparecida; MENDES-CORREA, Maria Cassia; PAULA, Anderson V. de; ROMANO, Camila M.; GOES, Luiz Gustavo Bentim; MINOPRIO, Paola; CAMPOS, Angelica C.; CUNHA, Marielton P.; VILELA, Ana Paula P.; NYIRENDA, Tonney; MKAKOSYA, Rajhab Sawasawa; MUULA, Adamson S.; DUMM, Rebekah E.; HARRIS, Rebecca M.; MITCHELL, Constance A.; PETTIT, Syril; BOTTEN, Jason; JEROME, Keith R.
    Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is used worldwide to test and trace the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ""Extraction-less"" or ""direct"" real time-reverse transcription polymerase chain reaction (RT-PCR) is a transparent and accessible qualitative method for SARS-CoV-2 detection from nasopharyngeal or oral pharyngeal samples with the potential to generate actionable data more quickly, at a lower cost, and with fewer experimental resources than full RT-qPCR. This study engaged 10 global testing sites, including laboratories currently experiencing testing limitations due to reagent or equipment shortages, in an international interlaboratory ring trial. Participating laboratories were provided a common protocol, common reagents, aliquots of identical pooled clinical samples, and purified nucleic acids and used their existing in-house equipment. We observed 100% concordance across laboratories in the correct identification of all positive and negative samples, with highly similar cycle threshold values. The test also performed well when applied to locally collected patient nasopharyngeal samples, provided the viral transport media did not contain charcoal or guanidine, both of which appeared to potently inhibit the RT-PCR reaction. Our results suggest that direct RT-PCR assay methods can be clearly translated across sites utilizing readily available equipment and expertise and are thus a feasible option for more efficient COVID-19 coronavirus disease testing as demanded by the continuing pandemic.
  • article 11 Citação(ões) na Scopus
    Torquetenovirus in saliva: A potential biomarker for SARS-CoV-2 infection?
    (2021) MENDES-CORREA, Maria C.; TOZETTO-MENDOZA, Tania Regina; FREIRE, Wilton S.; PAIAO, Heuder G. O.; FERRAZ, Andrea B. C.; MAMANA, Ana C.; FERREIRA, Noely E.; V, Anderson de Paula; FELIX, Alvina C.; ROMANO, Camila M.; BRAZ-SILVA, Paulo H.; LEAL, Fabio E.; GRESPAN, Regina M. Z.; SABINO, Ester C.; COSTA, Silvia F.; WITKIN, Steven S.
    Torquetenovirus (TTV) is present in biological fluids from healthy individuals and measurement of its titer is used to assess immune status in individuals with chronic infections and after transplants. We assessed if the titer of TTV in saliva varied with the presence of SARS-CoV-2 in the nasopharynx and could be a marker of COVID-19 status. Saliva from 91 individuals positive for SARS-CoV-2 in nasal-oropharyngeal samples, and from 126 individuals who were SARS-CoV-2-negative, all with mild respiratory symptoms, were analyzed. Both groups were similar in age, gender, symptom duration and time after symptom initiation when saliva was collected. Titers of TTV and SARS-CoV-2 were assessed by gene amplification. Loss of smell (p = 0.0001) and fever (p = 0.0186) were more prevalent in SARS-CoV-2-positive individuals, while sore throat (p = 0.0001), fatigue (p = 0.0037) and diarrhea (p = 0.0475) were more frequent in the SARS-CoV-2 negative group. The saliva TTV and nasal-oropharyngeal SARS-CoV-2 titers were correlated (p = 0.0085). The TTV level decreased as symptoms resolved in the SARS-CoV-2 infected group (p = 0.0285) but remained unchanged in the SARS-CoV-2 negative controls. In SARS-CoV-2 positive subjects who provided 2-4 saliva samples and in which TTV was initially present, the TTV titer always decreased over time as symptoms resolved. We propose that sequential TTV measurement in saliva is potentially useful to assess the likelihood of symptom resolution in SARS-CoV-2-positive individuals and to predict prognosis.
  • article 4 Citação(ões) na Scopus
    Modulated Zika virus NS1 conjugate offers advantages for accurate detection of Zika virus specific antibody in double antigen binding and Ig capture enzyme immunoassays
    (2019) TEDDER, Richard S.; DICKS, Steve; IJAZ, Samreen; SOUZA, Nathalia Caroline Santiago de; PAULA, Anderson Vincente de; LEVY, Flavia; MEDIALDEA-CARRERA, Raquel; LEVI, Jose Eduardo; PANNUTI, Claudio S.; SEQUEIRA, Patricia Carvalho de; BROWN, David W. G.; LUMB, Ines Ushiro
    The accurate diagnosis and seroprevalence investigations of Zika virus (ZKV) infections remain complex due to cross reactivity with other flaviviruses. Two assay formats, both using labelled Zika virus NS1 antigen as a revealing agent (a double antigen binding assay, DABA, and an immunoglobulin Ig capture assay, G capture) were initially developed and compared with the indirect EuroimmunZ assay for the detection of anti-Zika antibody. Of 147 pre-Zika period serum samples, 39 (27%) were reactive in the EuroimmunZ or the DABA assays, 28 sera concordantly so. Such false reactivity was influenced by the serotype of Dengue virus (DV) to which individuals had been exposed to. Thus, of sera from patients undergoing secondary Dengue virus infection of known serotype, 91%, 45% and 28% of Dengue virus serotype 2, 3 and 4 respectively were reactive in one or more of the three assays. A novel method of quenching false sero-reactivity was therefore developed for the DABA and G capture assays. Initial addition of a single homologous Dengue virus serotype 3 NS1Ag quench significantly ablated false reactivities in the pre-Zika period sera. An equipotent quadrivalent quench comprising homologous Dengue virus serotypes 1 to 4 NS1Ag was shown to be optimum yet retained sensitivity for the detection of specific anti-Zika antibody. Comparing DABA and G capture assays using quenched and unquenched conjugates in comparison with EuroimmunZ early in the course of PCR-confirmed infection indicated that a significant component of the apparent early anti-ZIKA antibody response is likely to be due to a Zika virus-driven anamnestic anti-Dengue virus response. The increased specificity provided by homologous antigen quenching is likely to provide a significant improvement in sero-diagnostics and to be of clinical value.